Last week, the Food and Drug Administration (FDA) listened to presentations and comments from several members of an expert FDA advisory committee regarding the benefit-to-risk ratio of Long Acting Beta-agonist drugs (LABAs) -- namely Serevent (salmeterol) , Foradil (formoterol) , Advair (a combination of fluticasone and salmeterol) and Symbicort (a combination of budesonide and formoterol).
The FDA advisory panel voted, unanimously, that the benefit of Advair and Symbicort outweighed the risks of adverse effects in adults , but that the risks of Serevent and Foradil -- particularly when used without a anti-inflammatory steroid -- outweighed the benefits for asthmatics.
So, what does all of this mean for you?
Continue reading "Advair and Symbicort: "Benefits Outweight the Risk" Says an FDA Advisory Comittee.
Get more information on Advair, Symbicort and Long-Acting Beta Agonists here.
Some of the most effective asthma medicines are inhaled steroids, and the downside to this is that the word "steroid" has a bad reputation. But what many people don't understand is that the steroids that have caused that negative publicity are NOT the kind of steroids that asthma sufferers take. In fact, the steroids that people are fearful of are called anabolic steroids, artificial substances used by some bodybuilders and athletes to build bigger muscles and enhance athletic performance. This type of steroids bears no resemblance to the inhaled steroids you may be taking. Inhaled steroids are actually very similar to natural substances in your own body. Although all medicines can cause side effects, the inhaled steroids used for asthma have proven to be very safe. Most side effects, if they do occur, lessen or even disappear over time. And the benefits greatly outweigh any risks, at any rate. However, other long-term asthma medications that are sometimes...
While the economy sputters, the long acting bronchodilator/ corticosteroid combination inhaler market is booming. While big pharmaceutical companies fight it out to maintain or gain a piece of this pie, we asthmatics should be the beneficiaries.
New drugs, and new marketing ploys, may soon be available in the U.S. market to compete with Advair and Symbicort, which will provide more options for asthmatics like you and me. Plus, as we all know, more competition means lower costs.
Advair and Symbicort are asthma combination inhalers that have both a long acting bronchodilator (LAB) to treat the airway narrowing (bronchospasm) component of asthma, but also a corticosteroid to treat the chronic inflammation side of asthma.
Advair (called Seritide in Europe), which is marketed by GlaxoSmithKline (GSK) out of London, became available in the U.S. in 2001, and presently has the lead in this booming market. Adviar consists of the LAB Salmeterol (Serev...
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.